[Estimation of the teratogenic effects of therapeutic drugs]

Acta Zoologica Et Pathologica Antverpiensia
|October 1, 1980
PubMed

Insights

Experimental procedures can detect teratogenic risks in animals. However, highly teratogenic effects are rare, requiring specific conditions for manifestation, necessitating careful risk-benefit analysis for new therapeutics.

Area of Science:

  • Pharmacology and Toxicology
  • Developmental Biology
  • Risk Assessment

Context:

  • Current experimental models are established for detecting potential teratogenic risks of therapeutics in laboratory animals.
  • The manifestation of teratogenic effects is contingent upon specific conditions, including embryonic stage, genetic factors, and maternal physiology.
  • Extrapolation of animal study findings to human subjects presents challenges.

Purpose:

  • To evaluate the efficacy of existing experimental procedures in identifying teratogenic risks associated with new therapeutics.
  • To highlight the complex interplay of factors influencing teratogenicity.
  • To emphasize the need for robust data interpretation in drug development.

Summary:

  • Experimental models effectively identify potential teratogenic risks in animals.
  • Highly teratogenic outcomes are improbable, requiring precise conditions like embryonic sensitivity, maternal health, and genetic makeup.
  • Challenges in extrapolating animal data necessitate the use of multiple species and historical control data for comprehensive risk-benefit assessment.

Impact:

  • Informs regulatory agencies and pharmaceutical developers on the interpretation of preclinical safety data.
  • Contributes to the development of safer therapeutics by refining risk assessment strategies.
  • Enhances the understanding of factors influencing developmental toxicity, aiding in the design of more predictive preclinical studies.

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...